Speaker Profile

M.D., M.H.S., Ph.D., Associate Professor, Division of Infectious Diseases, Duke Center for Applied Genomics & Precision Medicine, and the Department of Molecular Genetics & Microbiology, Duke University School of Medicine

Biography
Dr. Tsalik obtained his MD/PhD from Columbia University followed by residency in Internal Medicine and fellowship in Infectious Diseases at Duke University where he concurrently obtained a Masters of Health Science in Clinical Research. Dr. Tsalik’s research evaluates existing and emerging biomarkers, develops diagnostic platforms for pathogen identification and characterization, and has established a new paradigm for host response-based diagnostics. His research has been supported by DARPA, DTRA, VA, CDMRP/U.S. Army, and the NIH by way of the Antibacterial Resistance Leadership Group (ARLG) where Dr. Tsalik serves as the Associate Director of the ARLG Laboratory Center. His discoveries were the basis for the foundation of Predigen, a precision medicine diagnostics company. In 2021, Predigen merged with Biomeme, where Dr. Tsalik now serves as Chief Medical Officer. Biomeme’s vision is to empower anyone, anywhere with the knowledge to realize One Health.


 Session Abstract – PMWC 2022 Silicon Valley


Large-scale genomic sequencing efforts are of ever-increasing importance especially in the context of early pathogen detection, disease outbreak prevention, and establishing a predictive and efficient public health response. Rapid generation and access to genomic sequence data for viruses and other pathogens, which could cause a pandemic or serious outbreak, enables the tracking of variants and emerging pathogens (e.g., SARS-CoV-2, influenza, enterovirus D68, antibiotic-resistant bacteria, etc.), and thus the expedient development of diagnostics, vaccines, and therapeutics essential to supporting public health responses. This very important subject will be the focus of this session.